MedPage Today May 3, 2024
— Researchers are eyeing catheter-based delivery for people with refractory angina
LONG BEACH, Calif. — A gene therapy for therapeutic angiogenesis showed promise for people with angina who had already exhausted their options for medical therapy and coronary revascularization, according to the single-arm phase I/II EXACT trial.
Identified as having so-called “no option” refractory angina, 32 study participants agreed to try one dose of XC001 — an engineered adenovirus vector that transiently increases VEGF-A expression in the myocardium — administered via direct transepicardial delivery following a minithoracotomy. The therapy is intended to target microvascular dysfunction and ischemia.
Results of the treatment showed no serious adverse events (SAEs) or off-target effects related to XC001 — instead, there were 20 events possibly...
Today's Sponsors
Today's Sponsor